Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDifferential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: Interaction studies with citalopram
European Neuropsychopharmacology, 07/16/09
Gannon RL et al. - The authors evaluated their influence on suppression of phase advances by citalopram. Its action was potentiated by WAY100635 and the 5-HT2C antagonist, SB242084, but not by A842377, SB224289, SB269970, and antagonists at 5-HT2A and 5-HT6 receptors. In conclusion, this is the first in vivo evidence for an influence of 5-HT5A receptors upon circadian rhythms, but no single class of 5-HT receptor mediates their control by citalopram.
Related Articles
Spatiotemporally separable Shh domains in the midbrain define distinct dopaminergic progenitor pools
Proceedings of the National Academy of Sciences of the United States of America, 11/11/09
Relevance Score: 43%
Bilateral caudate nucleus infarction resulting from left ventricular diastolic dysfunction
Central European Journal of Medicine, 10/27/09
Relevance Score: 43%
Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions
Pharmacological Reviews, 10/15/09
Relevance Score: 43%
Distinct striatal targets in treating obsessive-compulsive disorder and major depression
Journal of Neurosurgery, 10/06/09
Relevance Score: 42%
Susceptibility-Enhanced 3-Tesla T1-Weighted Spoiled Gradient Echo of the Midbrain Nuclei for Guidance of Deep Brain Stimulation Implantation
Neurosurgery, 10/05/09
Relevance Score: 42%
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
First-in-Human Study Demonstrating Pharmacological Activation of Heme Oxygenase-1 in Humans
Clinical Pharmacology & Therapeutics, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor